Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating ABBV-CLS-7262 for the Treatment of Vanishing White Matter Disease

SOUTH SAN FRANCISCO, Calif., April 26, 2023 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and healthspan, and founded by Alphabet and Arthur D. Levinson Ph.D., today announced that the first participant has been dosed in a...

Click to view original post